Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02975206 · ClinicalTrials.gov registry record · Phase 2
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
A Phase 2 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 484
- Enrollment target
NCT02975206: Completed Phase 2 study, sponsored by Vyne Therapeutics.
NCT02975206 is a Phase 2 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 484 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (264% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02975206, a Phase 2 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 484 participants
- Enrollment target
Study Summary
Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
Primary Outcome
Worst Itch Numeric Rating Scale (WI-NRS). 11-point scale ranging from 0 (no itch) to 10 (worst itch imaginable). Higher scores indicate greater itch intensity. The primary outcome is the change in WI-NRS score between the visit and Baseline.
Interventions
- DRUG Placebo Oral Tablet
- DRUG Serlopitant High Dose
- DRUG Serlopitant Low Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 484 participants |
| Start Date | 2016-11 |
| Est. Completion | 2018-02-23 |
| Phase | Phase 2 |
What the finished NCT02975206 record still lists
NCT02975206 is an interventional study that assigns participants to a tested intervention. The registered 484 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (264% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo Oral Tablet is the first listed.
NCT02975206 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02975206 about?
NCT02975206 is a clinical study titled "Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis". Study of the Efficacy, Safety, and Tolerability of Serlopitant for Pruritus (Itch) in Atopic Dermatitis
What is the current status of trial NCT02975206?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 484 participants. The study started on 2016-11. Estimated completion is 2018-02-23.
What interventions are being tested in trial NCT02975206?
The interventions under investigation include: Placebo Oral Tablet (DRUG), Serlopitant High Dose (DRUG), Serlopitant Low Dose (DRUG).
Who is sponsoring clinical trial NCT02975206?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02975206's enrollment target sits among peer trials
484 76th of 2000 higher than 1,925 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05421741 · 484 participants · Phase 4
Prophylactic Antibiotic Coated Nail to Prevent Infection: A Clinical Trial
- NCT07124910 · 485 participants · Phase 3
Comparison of Epi-ON Corneal Collagen Crosslinking Performed Using an 18-Minute UVA Exposure vs. a 24-Minute UVA Exposure on Eyes With Ectatic Corneal Diseases
- NCT02871726 · 483 participants · NA
Transrectal Ultrasound Robot-Assisted Prostate Biopsy
- NCT06420531 · 486 participants · NA
Milk And Growth In Children (MAGIC) Born Very Preterm: A Randomized Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia